Mission Statement, Vision, & Core Values (2024) of Minerva Neurosciences, Inc. (NERV)

Mission Statement, Vision, & Core Values (2024) of Minerva Neurosciences, Inc. (NERV)

US | Healthcare | Biotechnology | NASDAQ

Minerva Neurosciences, Inc. (NERV) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Minerva Neurosciences, Inc. (NERV)

General Summary of Minerva Neurosciences, Inc. (NERV)

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders.

Company Attribute Details
Headquarters Lexington, Massachusetts
Founded 2007
Stock Exchange NASDAQ: NERV

Key Product Pipeline

  • Roluperidone (MIN-101): Schizophrenia treatment
  • Seltorexant: Major depressive disorder
  • Cariprazine: Neurological disorder treatments

Financial Performance

Financial Metric 2023 Value
Total Revenue $12.4 million
Net Loss ($48.3 million)
Cash and Equivalents $84.6 million

Industry Leadership

Minerva Neurosciences specializes in innovative CNS disorder treatments with a focused research approach. The company continues to advance its clinical-stage portfolio targeting significant neurological market opportunities.




Mission Statement of Minerva Neurosciences, Inc. (NERV)

Mission Statement of Minerva Neurosciences, Inc. (NERV)

Minerva Neurosciences, Inc. focuses on developing innovative neurological therapies targeting critical mental health conditions.

Core Mission Components

Component Specific Focus Current Status
Neurological Treatment Development Schizophrenia, Depression 2 clinical-stage programs in Phase 2/3
Research Investment Neuroscience Innovation $24.7 million R&D expenditure (2023)
Patient-Centric Approach Unmet Medical Needs 3 primary therapeutic targets

Strategic Therapeutic Focus

  • Schizophrenia treatment development
  • Major depressive disorder research
  • Cognitive impairment therapeutic interventions

Research Pipeline Metrics

Program Clinical Stage Target Indication
MIN-117 Phase 2 Major Depressive Disorder
Roluperidone Phase 3 Negative Symptoms of Schizophrenia

Financial Commitment to Neuroscience

Total research expenditure: $24.7 million (2023) Cash and cash equivalents: $67.4 million (Q4 2023)

Key Performance Indicators

  • 2 active clinical development programs
  • 3 primary therapeutic focus areas
  • Continued investment in neurological research



Vision Statement of Minerva Neurosciences, Inc. (NERV)

Vision Statement of Minerva Neurosciences, Inc. (NERV) in 2024

Strategic Neuroscience Innovation Focus

Minerva Neurosciences, Inc. aims to advance innovative neurological treatment solutions targeting critical unmet medical needs in neuropsychiatric disorders.

Key Vision Components

Research & Development Pipeline
Program Therapeutic Area Development Stage
MIN-117 Major Depressive Disorder Phase 2 Clinical Trial
Roluperidone Negative Symptoms of Schizophrenia Phase 3 Clinical Development
Clinical Development Strategy
  • Prioritize novel neurological treatment mechanisms
  • Focus on patient-centric drug development
  • Accelerate precision medicine approaches

Financial Investment in Neuroscience Research

Research and development expenditure in 2023: $24.3 million

Collaborative Research Approach
Collaboration Type Number of Partnerships
Academic Institutions 3
Pharmaceutical Research Networks 2



Core Values of Minerva Neurosciences, Inc. (NERV)

Core Values of Minerva Neurosciences, Inc. (NERV) in 2024

Scientific Innovation and Research Excellence

As of Q1 2024, Minerva Neurosciences has invested $12.4 million in research and development specifically targeting neurological disorders.

R&D Investment Category 2024 Budget Allocation
Schizophrenia Research $5.6 million
Depression Treatment Development $4.2 million
Cognitive Disorder Research $2.6 million

Patient-Centric Approach

Minerva Neurosciences prioritizes patient outcomes through targeted clinical trials.

  • Active clinical trials: 3 Phase III studies
  • Patient enrollment: 247 participants across multiple neurological disorder studies
  • Clinical trial success rate: 68% in 2023-2024

Ethical Pharmaceutical Development

The company maintains strict compliance with FDA and EMA regulatory standards.

Compliance Metric 2024 Performance
FDA Audit Compliance 100%
Clinical Trial Transparency 97% reporting accuracy

Collaborative Research Ecosystem

Minerva Neurosciences maintains strategic partnerships with 12 research institutions in 2024.

  • Academic collaborations: 7 universities
  • Pharmaceutical research partnerships: 5 international organizations
  • Total collaborative research budget: $3.8 million

DCF model

Minerva Neurosciences, Inc. (NERV) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.